Mutation News and Research

RSS

American Thoracic Society, IASLC and ERS propose new sub-classification of lung adenocarcinomas

The International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS), have proposed a new sub-classification of lung adenocarcinomas.

16 Dec 2012

Iclusig gets FDA approval for two rare blood and bone marrow diseases

The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.

15 Dec 2012

Researchers identify how RecA protein helps broken DNA find way to bridge the gap

Every time a human or bacterial cell divides it first must copy its DNA. Specialized proteins unzip the intertwined DNA strands while others follow and build new strands, using the originals as templates. Whenever these proteins encounter a break - and there are many - they stop and retreat, allowing a new cast of molecular players to enter the scene.

14 Dec 2012

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.

14 Dec 2012

Study finds new evidence that vitamin D decreases risk of autism in children

A study just published online in the peer-reviewed journal Dermato-Endocrinology found additional evidence that vitamin D reduces the risk of developing autism.

14 Dec 2012

Biological factors, cell behaviour drive tumour growth contributing to therapy failure and relapse

Cancer scientists led by Dr. John Dick at the Princess Margaret Cancer Centre have found a way to follow single tumour cells and observe their growth over time. By using special immune-deficient mice to propagate human colorectal cancer, they found that genetic mutations, regarded by many as the chief suspect driving cancer growth, are only one piece of the puzzle. The team discovered that biological factors and cell behaviour - not only genes - drive tumour growth, contributing to therapy failure and relapse.

14 Dec 2012

TUBB5 gene responsible for microcephaly: IMP study

Neurobiologists at the Research institute of Molecular Pathology (IMP) in Vienna have discovered one of the key genes required to make a brain. Mutations in this gene, called TUBB5, cause neurodevelopmental disease in children.

14 Dec 2012

Pairing statins with cyclin-dependent kinase inhibitors might effectively treat melanomas

A novel approach to identifying potential anticancer drug combinations revealed that pairing cholesterol-reducing drugs called statins with cyclin-dependent kinase inhibitors might provide an effective approach to treating intractable melanomas driven by mutations in the NRAS and KRAS gene.

14 Dec 2012

Scientists identify new mutation in a gene that causes Alpha-1 Antitrypsin Deficiency

Scientists have identified a new mutation in the gene that causes the inherited disease known as Alpha-1 Antitrypsin Deficiency (Alpha-1), which affects roughly one in 2,500 people of European descent.

14 Dec 2012

Computer simulation can predict risk of irregular heart rhythms and sudden cardiac death

A computer model of the heart wall predicted risk of irregular heart rhythms and sudden cardiac death in patients, paving the way for the use of more complex cardiac models to calculate the consequences of genetic, lifestyle and other changes to the heart.

14 Dec 2012

Dantrolene may help combat Duchenne muscular dystrophy in boys

Drugs are currently being tested that show promise in treating patients with Duchenne muscular dystrophy (DMD), an inherited disease that affects about one in 3,600 boys and results in muscle degeneration and, eventually, death.

13 Dec 2012

Study finds many patients with family history of LINE-1 hypomethylated colorectal cancer

When people with a family history of colorectal cancer develop the disease, their tumors often carry a molecular sign that the cancer could be life-threatening and may require aggressive treatment, Dana-Farber Cancer Institute scientists report in a new study.

13 Dec 2012

TKI-resistant human leukemia stem cells are the source of genomic instability

An international team of scientists, led by researchers from Temple University School of Medicine, has found that a source of mounting genomic chaos, or instability, common to chronic myeloid leukemia (CML) may lie in a pool of leukemia stem cells that are immune to treatment with potent targeted anticancer drugs.

12 Dec 2012

Review describes current state of lung cancer care

A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care.

12 Dec 2012

Link between CTNNA3 gene mutations and arrhythmogenic right ventricular cardiomyopathy

Unfortunately, newspaper articles about young athletes dying suddenly on the field are not unheard of. Such reports fuel discussions about compulsory screening, for example of young footballers, for heart failure. Research by scientists from Ghent (VIB/UGent) and Italy will benefit these screening methods.

12 Dec 2012

Researchers decipher mechanism by which anophelin binds to thrombin

An international project lead by the Molecular and Cell Biology Institute of Porto University with the participation of researchers from IMIM (Hospital del Mar Medical Research Institute) has, for the first time ever, deciphered the mechanism by which a substance called anophelin binds to an enzyme (thrombin) involved in the process of blood coagulation.

12 Dec 2012

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Astellas Pharma Inc. and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Mutation News and Research

American Thoracic Society, IASLC and ERS propose new sub-classification of lung adenocarcinomas

Iclusig gets FDA approval for two rare blood and bone marrow diseases

Researchers identify how RecA protein helps broken DNA find way to bridge the gap

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

Study finds new evidence that vitamin D decreases risk of autism in children

Biological factors, cell behaviour drive tumour growth contributing to therapy failure and relapse

TUBB5 gene responsible for microcephaly: IMP study

Pairing statins with cyclin-dependent kinase inhibitors might effectively treat melanomas

Scientists identify new mutation in a gene that causes Alpha-1 Antitrypsin Deficiency

Computer simulation can predict risk of irregular heart rhythms and sudden cardiac death

Dantrolene may help combat Duchenne muscular dystrophy in boys

Study finds many patients with family history of LINE-1 hypomethylated colorectal cancer

TKI-resistant human leukemia stem cells are the source of genomic instability

Review describes current state of lung cancer care

Link between CTNNA3 gene mutations and arrhythmogenic right ventricular cardiomyopathy

Researchers decipher mechanism by which anophelin binds to thrombin

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

uniQure commences acute intermittent porphyria Phase I clinical trial

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News